{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T07:41:51Z","timestamp":1791013311029,"version":"4.1.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T00:00:00Z","timestamp":1475798400000},"content-version":"vor","delay-in-days":2685,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1038\/mt.2009.53","type":"journal-article","created":{"date-parts":[[2009,3,17]],"date-time":"2009-03-17T15:45:05Z","timestamp":1237304705000},"page":"964-971","source":"Crossref","is-referenced-by-count":135,"title":["The Pharmacological Chaperone N-butyldeoxynojirimycin Enhances Enzyme Replacement Therapy in Pompe Disease Fibroblasts"],"prefix":"10.1016","volume":"17","author":[{"given":"Caterina","family":"Porto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Cardone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rosaria","family":"Tuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonietta","family":"Tarallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Vittoria","family":"Barone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Generoso","family":"Andria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Parenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/mt.2009.53_bib1","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/nrm1423","article-title":"The cell biology of lysosomal storage disorders","volume":"5","author":"Futerman","year":"2004","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1038\/mt.2009.53_bib2","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/nrn1725","article-title":"Storage solutions: treating lysosomal disorders of the brain","volume":"6","author":"Jeyakumar","year":"2005","journal-title":"Nat Rev Neurosci"},{"key":"10.1038\/mt.2009.53_bib3","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.jpeds.2007.04.054","article-title":"Hematopoietic cell therapy for metabolic disease","volume":"151","author":"Orchard","year":"2007","journal-title":"J Pediatr"},{"key":"10.1038\/mt.2009.53_bib4","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1146\/annurev.med.57.110104.115650","article-title":"Enzyme replacement for lysosomal diseases","volume":"57","author":"Brady","year":"2006","journal-title":"Annu Rev Med"},{"key":"10.1038\/mt.2009.53_bib5","doi-asserted-by":"crossref","first-page":"43R","DOI":"10.1093\/glycob\/cwi076","article-title":"Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses","volume":"15","author":"Butters","year":"2005","journal-title":"Glycobiology"},{"key":"10.1038\/mt.2009.53_bib6","doi-asserted-by":"crossref","first-page":"4962","DOI":"10.1111\/j.1742-4658.2007.06041.x","article-title":"Active-site-specific chaperone therapy for Fabry disease. Yin and Yang of enzyme inhibitors","volume":"274","author":"Fan","year":"2007","journal-title":"FEBS J"},{"key":"10.1038\/mt.2009.53_bib7","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s10545-008-0873-2","article-title":"Potential efficacy of enzyme replacement and substrate reduction therapy in three siblings with Gaucher disease type III","volume":"31","author":"Cox-Brinkman","year":"2008","journal-title":"J Inherit Metab Dis"},{"key":"10.1038\/mt.2009.53_bib8","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1651-2227.2008.00656.x","article-title":"Substrate reduction therapy","volume":"97","author":"Platt","year":"2008","journal-title":"Acta Paediatr Suppl"},{"key":"10.1038\/mt.2009.53_bib9","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/sj.bmt.1705934","article-title":"Combination of enzyme replacement and hematopoietic stem cell transplantation as therapy for Hurler syndrome","volume":"41","author":"Tolar","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1038\/mt.2009.53_bib10","series-title":"The Metabolic and Molecular Bases of Inherited Disease","first-page":"3389","article-title":"Glycogen storage disease type II: acid a-glucosidase (acid maltase) deficiency","author":"Hirschhorn","year":"2001"},{"key":"10.1038\/mt.2009.53_bib11","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","article-title":"Pompe's disease","volume":"372","author":"van der Ploeg","year":"2008","journal-title":"Lancet"},{"key":"10.1038\/mt.2009.53_bib12","doi-asserted-by":"crossref","first-page":"546","DOI":"10.4161\/auto.4591","article-title":"Deconstructing Pompe disease by analyzing single muscle fibers: to see a world in a grain of sand","volume":"3","author":"Raben","year":"2007","journal-title":"Autophagy"},{"key":"10.1038\/mt.2009.53_bib13","first-page":"45","article-title":"Role of autophagy in the pathogenesis of Pompe disease","volume":"26","author":"Raben","year":"2007","journal-title":"Acta Myol"},{"key":"10.1038\/mt.2009.53_bib14","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1542\/peds.112.2.332","article-title":"The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature","volume":"112","author":"van den Hout","year":"2003","journal-title":"Pediatrics"},{"key":"10.1038\/mt.2009.53_bib15","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/j.jpeds.2004.01.053","article-title":"Pompe disease in infants and children","volume":"144","author":"Kishnani","year":"2004","journal-title":"J Pediatr"},{"key":"10.1038\/mt.2009.53_bib16","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jpeds.2005.11.033","article-title":"A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease","volume":"148","author":"Kishnani","year":"2006","journal-title":"J Pediatr"},{"key":"10.1038\/mt.2009.53_bib17","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(00)02533-2","article-title":"Recombinant human \u03b1-glucosidase from rabbit milk in Pompe patients","volume":"356","author":"van den Hout","year":"2000","journal-title":"Lancet"},{"key":"10.1038\/mt.2009.53_bib18","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1542\/peds.113.5.e448","article-title":"Long-term intravenous treatment of Pompe disease with recombinant human \u03b1-glucosidase from milk","volume":"113","author":"Van den Hout","year":"2004","journal-title":"Pediatrics"},{"key":"10.1038\/mt.2009.53_bib19","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/labinvest.3700484","article-title":"Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease","volume":"86","author":"Thurberg","year":"2006","journal-title":"Lab Invest"},{"key":"10.1038\/mt.2009.53_bib20","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1212\/01.wnl.0000319722.16673.27","article-title":"Enzyme replacement therapy for infantile onset pompe disease: curse or cure?","volume":"71","author":"Willems","year":"2008","journal-title":"Neurology"},{"key":"10.1038\/mt.2009.53_bib21","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.nurt.2008.08.009","article-title":"Therapeutic approaches in glycogen storage disease type II\/Pompe disease","volume":"5","author":"Schoser","year":"2008","journal-title":"Neurotherapeutics"},{"key":"10.1038\/mt.2009.53_bib22","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ymgme.2003.08.022","article-title":"Enzyme replacement therapy in the mouse model of Pompe disease","volume":"80","author":"Raben","year":"2003","journal-title":"Mol Genet Metab"},{"key":"10.1038\/mt.2009.53_bib23","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ymthe.2006.08.009","article-title":"Autophagy and mistargeting of therapeutic enzyme in skeletal muscle in Pompe disease","volume":"14","author":"Fukuda","year":"2006","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2009.53_bib24","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1755-8417-1-6","article-title":"Abnormal mannose-6-phosphate receptor trafficking impairs recombinant \u03b1-glucosidase uptake in Pompe disease fibroblasts","volume":"1","author":"Cardone","year":"2008","journal-title":"Pathogenetics"},{"key":"10.1038\/mt.2009.53_bib25","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.bbadis.2008.03.001","article-title":"Rescue of mutant \u03b1-galactosidase A in the endoplasmic reticulum by 1-deoxygalactonojirimycin leads to trafficking to lysosomes","volume":"1782","author":"Hamanaka","year":"2008","journal-title":"Biochim Biophys Acta"},{"key":"10.1038\/mt.2009.53_bib26","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/4801","article-title":"Accelerated transport and maturation of lysosomal \u03b1-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor","volume":"5","author":"Fan","year":"1999","journal-title":"Nat Med"},{"key":"10.1038\/mt.2009.53_bib27","doi-asserted-by":"crossref","first-page":"15912","DOI":"10.1073\/pnas.2536657100","article-title":"Chemical chaperone therapy for brain pathology in (GM1)-gangliosidosis","volume":"100","author":"Matsuda","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1038\/mt.2009.53_bib28","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00018-008-7470-2","article-title":"Chemical chaperone therapy for GM1-gangliosidosis","volume":"65","author":"Suzuki","year":"2008","journal-title":"Cell Mol Life Sci"},{"key":"10.1038\/mt.2009.53_bib29","doi-asserted-by":"crossref","first-page":"13478","DOI":"10.1074\/jbc.M308523200","article-title":"Pharmacological enhancement of \u03b2-hexosaminidase activity in fibroblasts from adult Tay-Sachs and Sandhoff patients","volume":"279","author":"Tropak","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1038\/mt.2009.53_bib30","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1111\/j.1742-4658.2007.06042.x","article-title":"Pharmacologic chaperoning as a strategy to treat Gaucher disease","volume":"274","author":"Yu","year":"2007","journal-title":"FEBS J"},{"key":"10.1038\/mt.2009.53_bib31","doi-asserted-by":"crossref","first-page":"9150","DOI":"10.1074\/jbc.M609304200","article-title":"Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis","volume":"282","author":"Maegawa","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1038\/mt.2009.53_bib32","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ymgme.2006.09.010","article-title":"Chemical chaperones improve transport and enhance stability of mutant \u03b1-glucosidases in glycogen storage disease type II","volume":"90","author":"Okumiya","year":"2007","journal-title":"Mol Genet Metab"},{"key":"10.1038\/mt.2009.53_bib33","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/sj.mt.6300074","article-title":"Pharmacological enhancement of mutated \u03b1-glucosidase activity in fibroblasts from patients with Pompe disease","volume":"15","author":"Parenti","year":"2007","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2009.53_bib34","doi-asserted-by":"crossref","first-page":"3862","DOI":"10.1016\/S0021-9258(19)85604-1","article-title":"Substrate stabilization of lysozyme to thermal and guanidine hydrochloride denaturation","volume":"255","author":"Pace","year":"1980","journal-title":"J Biol Chem"},{"key":"10.1038\/mt.2009.53_bib35","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.bbrc.2008.02.125","article-title":"Isofagomine increases lysosomal delivery of exogenous glucocerebrosidase","volume":"369","author":"Shen","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1038\/mt.2009.53_bib36","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1016\/S0140-6736(00)02161-9","article-title":"Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis","volume":"355","author":"Cox","year":"2000","journal-title":"Lancet"},{"key":"10.1038\/mt.2009.53_bib37","doi-asserted-by":"crossref","first-page":"6780","DOI":"10.1074\/jbc.M404008200","article-title":"Lysosomal acid \u03b1-glucosidase consists of four different peptides processed from a single chain precursor","volume":"280","author":"Moreland","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1038\/mt.2009.53_bib38","first-page":"45","article-title":"Role of autophagy in the pathogenesis of Pompe disease","volume":"26","author":"Raben","year":"2007","journal-title":"Acta Myol"},{"key":"10.1038\/mt.2009.53_bib39","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1212\/01.wnl.0000299892.81127.8e","article-title":"Molecular pathology and enzyme processing in various phenotypes of acid maltase deficiency","volume":"70","author":"Nascimbeni","year":"2008","journal-title":"Neurology"},{"key":"10.1038\/mt.2009.53_bib40","first-page":"424","article-title":"Expression of the insulin-like growth factor-II\/mannose-6-phosphate receptor in multiple human tissues during fetal life and early infancy","volume":"75","author":"Funk","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1038\/mt.2009.53_bib41","first-page":"723","article-title":"Quantitation of Mr 46000 and Mr 300000 mannose 6-phosphate receptors in human cells and tissues","volume":"23","author":"Wenk","year":"1991","journal-title":"Biochem Int"},{"key":"10.1038\/mt.2009.53_bib42","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1093\/hmg\/7.11.1815","article-title":"Recombinant human acid \u03b1-glucosidase: high level production in mouse milk, biochemical characteristics, correction of enzyme deficiency in GSDII KO mice","volume":"7","author":"Bijvoet","year":"1998","journal-title":"Hum Mol Genet"},{"key":"10.1038\/mt.2009.53_bib43","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0021-9258(18)53985-5","article-title":"Structural and functional changes of lysosomal acid \u03b1-glucosidase during intracellular transport and maturation","volume":"268","author":"Wisselaar","year":"1993","journal-title":"J Biol Chem"},{"key":"10.1038\/mt.2009.53_bib44","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/humu.10286","article-title":"Twenty-two novel mutations in the lysosomal \u03b1-glucosidase gene (GAA) underscore the genotype-phenotype correlation in glycogen storage disease type II","volume":"23","author":"Hermans","year":"2004","journal-title":"Hum Mutat"},{"key":"10.1038\/mt.2009.53_bib45","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/humu.20374","article-title":"Mutation profile of the GAA gene in 40 Italian patients with late onset glycogen storage disease type II","volume":"27","author":"Montalvo","year":"2006","journal-title":"Hum Mutat"},{"key":"10.1038\/mt.2009.53_bib46","doi-asserted-by":"crossref","first-page":"E27","DOI":"10.1002\/humu.20753","article-title":"Molecular and functional characterization of eight novel GAA mutations in Italian infants with Pompe disease","volume":"29","author":"Pittis","year":"2008","journal-title":"Hum Mutat"},{"key":"10.1038\/mt.2009.53_bib47","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human \u03b1-galactosidase A replacement therapy in Fabry's disease","volume":"345","author":"Eng","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1038\/mt.2009.53_bib48","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1080\/00498250601094543","article-title":"The pharmacokinetics and tissue distribution of the glucosylceramide synthase inhibitor miglustat in the rat","volume":"37","author":"Treiber","year":"2007","journal-title":"Xenobiotica"},{"key":"10.1038\/mt.2009.53_bib49","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/0883073807302598","article-title":"Long-term enzyme replacement therapy for pompe disease with recombinant human \u03b1-glucosidase derived from chinese hamster ovary cells","volume":"22","author":"Rossi","year":"2007","journal-title":"J Child Neurol"},{"key":"10.1038\/mt.2009.53_bib50","doi-asserted-by":"crossref","first-page":"19086","DOI":"10.1074\/jbc.273.30.19086","article-title":"Targeted disruption of the acid \u03b1-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II","volume":"273","author":"Raben","year":"1998","journal-title":"J Biol Chem"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616318020?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616318020?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,10,3]],"date-time":"2021-10-03T09:16:44Z","timestamp":1633252604000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001616318020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["S1525001616318020"],"URL":"https:\/\/doi.org\/10.1038\/mt.2009.53","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2009,6]]}}}